Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 6Phase 2/3 4Phase 1/2 1Phase 1 1

Status

Unknown 4Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Oesophagogastric Cancer 1Breast Diseases 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Lapatinib × Clear all
NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

RemeGen Co., Ltd.

Phase 2/3 Unknown
301 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT03085368 2017-07-28

A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

Peking Union Medical College Hospital

Phase 2/3 Unknown
482 enrolled
Breast

Breast Neoplasms

NCT00450203 2016-12-01

ST03

Medical Research Council

Phase 2/3 Unknown
1,103 enrolled
Gastrointestinal

Oesophagogastric Cancer

NCT00949455 2015-04-15

LaMB

Queen Mary University of London

Phase 2/3 Unknown
204 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡